Anne Morosky

2.0k total citations · 2 hit papers
13 papers, 1.3k citations indexed

About

Anne Morosky is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anne Morosky has authored 13 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 4 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anne Morosky's work include Cancer Immunotherapy and Biomarkers (10 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Cancer Research and Treatments (2 papers). Anne Morosky is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Cancer Research and Treatments (2 papers). Anne Morosky collaborates with scholars based in United States, France and United Kingdom. Anne Morosky's co-authors include Sanatan Saraf, Bilal Piperdi, Patrick A. Ott, Emilie M.J. van Brummelen, Juanita Lopez, Armando Santoro, Evan Alley, Sandrine Hiret, Janice M. Mehnert and Élena Elez and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Anne Morosky

13 papers receiving 1.3k citations

Hit Papers

Pembrolizumab in Patients With Extensive-Stage Small-Cell... 2017 2026 2020 2023 2017 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    2017 363 citations Patrick A. Ott, Élena Elez et al. Journal of Clinical Oncology profile →
  2. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    2017 325 citations Evan Alley, Juanita Lopez et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne Morosky United States 12 874 492 287 228 206 13 1.3k
Austin Doyle United States 15 423 0.5× 311 0.6× 109 0.4× 413 1.8× 112 0.5× 33 1.0k
Kyaw Aung Canada 11 534 0.6× 146 0.3× 146 0.5× 129 0.6× 78 0.4× 21 806
Biagio Paolini Italy 20 305 0.3× 213 0.4× 86 0.3× 325 1.4× 318 1.5× 80 1.0k
Frank Priou France 15 621 0.7× 563 1.1× 37 0.1× 250 1.1× 219 1.1× 63 1.1k
Jonathan C. Dudley United States 15 937 1.1× 495 1.0× 124 0.4× 380 1.7× 475 2.3× 24 1.5k
Pier Selenica United States 21 424 0.5× 324 0.7× 107 0.4× 312 1.4× 194 0.9× 77 1.2k
Anna Pesci Italy 17 302 0.3× 244 0.5× 503 1.8× 312 1.4× 362 1.8× 42 1.3k
Bin Meng China 18 334 0.4× 186 0.4× 133 0.5× 245 1.1× 152 0.7× 62 814
E. Kutarska Poland 12 440 0.5× 96 0.2× 34 0.1× 274 1.2× 178 0.9× 17 939
Yuezong Bai China 15 629 0.7× 402 0.8× 51 0.2× 248 1.1× 149 0.7× 60 987

Countries citing papers authored by Anne Morosky

Since Specialization
Citations

This map shows the geographic impact of Anne Morosky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Morosky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Morosky more than expected).

Fields of papers citing papers by Anne Morosky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Morosky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Morosky. The network helps show where Anne Morosky may publish in the future.

Co-authorship network of co-authors of Anne Morosky

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Morosky. A scholar is included among the top collaborators of Anne Morosky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Morosky. Anne Morosky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Varga, Andréa, Sarina A. Piha‐Paul, Patrick A. Ott, et al.. (2018). Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecologic Oncology. 152(2). 243–250. 198 indexed citations
2.
Alley, Evan, Juanita Lopez, Armando Santoro, et al.. (2017). OA13.03 Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028. Journal of Thoracic Oncology. 12(1). S294–S294. 10 indexed citations
3.
Ott, Patrick A., Sarina A. Piha‐Paul, Pamela N. Münster, et al.. (2017). Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology. 28(5). 1036–1041. 164 indexed citations
4.
Alley, Evan, Juanita Lopez, Armando Santoro, et al.. (2017). Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. The Lancet Oncology. 18(5). 623–630. 325 indexed citations breakdown →
5.
Ott, Patrick A., Enriqueta Felip, Sandrine Hiret, et al.. (2017). OA05.01 Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028. Journal of Thoracic Oncology. 12(1). S259–S259. 15 indexed citations
6.
Ott, Patrick A., Élena Elez, Sandrine Hiret, et al.. (2017). Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. Journal of Clinical Oncology. 35(34). 3823–3829. 363 indexed citations breakdown →
7.
Varga, Andréa, Sarina A. Piha‐Paul, Patrick A. Ott, et al.. (2017). Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.. Journal of Clinical Oncology. 35(15_suppl). 5513–5513. 38 indexed citations
8.
Cohen, Roger B., Jean‐Pierre Delord, Toshihiko Doi, et al.. (2016). Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.. Journal of Clinical Oncology. 34(15_suppl). 6017–6017. 11 indexed citations
9.
Reardon, David A., Jean‐Sébastien Frenel, Armando Santoro, et al.. (2016). ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM). Neuro-Oncology. 18(suppl_6). vi25–vi26. 39 indexed citations
10.
Piha‐Paul, Sarina A., Pamela N. Münster, Michael J. Pishvaian, et al.. (2015). 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. European Journal of Cancer. 51. S102–S102. 12 indexed citations
11.
McDermott, David F., J. R. Infante, Martin H. Voss, et al.. (2015). 2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC). European Journal of Cancer. 51. S519–S520. 12 indexed citations
12.
Colombo, Nicoletta, D. Scott McMeekin, Peter E. Schwartz, et al.. (2013). Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. British Journal of Cancer. 108(5). 1021–1026. 84 indexed citations
13.
Khan, Khurum, Li Yan, Amita Patnaik, et al.. (2012). A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 30(15_suppl). e13599–e13599. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Austin Doyle Breakdown of academic impact, for papers by Kyaw Aung Breakdown of academic impact, for papers by Biagio Paolini Breakdown of academic impact, for papers by Frank Priou Breakdown of academic impact, for papers by Jonathan C. Dudley Breakdown of academic impact, for papers by Pier Selenica Breakdown of academic impact, for papers by Anna Pesci Breakdown of academic impact, for papers by Bin Meng Breakdown of academic impact, for papers by E. Kutarska Breakdown of academic impact, for papers by Yuezong Bai
Rankless by CCL
2026